Table 2.
Preexistent immunity to HLA-A2-restricted HER-2/neu–derived peptides representing CTL epitopes. Tetanus toxoid–specific CTL precursor frequencies (PFs) in the same patients (range 1:2,000–1:9,800). Range of peptide-specific mean CTL PFs of the various peptides in patients with HER-2/neu − tumors (1:98,500 to 1:176,400) and in healthy individuals (1:153,000 to 1:348,000)
| Type of cancer | HER-2/neu peptides | ||||
|---|---|---|---|---|---|
| p435–443 | p665–673 | p689–697 | p777–785 | p952–960 | |
| Breast | 1:13,500 | 1:12,900 | 1:16,700 | 1:11,900 | 1:4,000 |
| 1:13,300 | 1:17,500 | 1:14,700 | |||
| 1:18,200 | |||||
| Colorectal | 1:14,500 | 1:13,500 | |||
| 1:19,200 | 1:15,200 | ||||
| Lung | 1:13,900 | 1:13,300 | 1:8,200 | ||
| 1:9,800 | |||||
| Ovarian | 1:11,100 | 1:11,900 | 1:13,500 | 1:6,000 | |
| 1:15,600 | 1:14,900 | 1:9,900 | |||
| Prostate | 1:17,500 | 1:14,900 | 1:13,600 | ||